arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

QuidelOrtho Corp

QDEL
$10.35 ▼ -0.61 (-5.57%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
24 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

QuidelOrtho Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $706.9M
Dividend Yield —
Revenue Growth 2.8% ↗
Op. Margin -3.5% ↗
ROIC -1.4% ↗
FCF / Share $-1.99 ↘
Trailing P/E —
Price / Book 0.4x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$630.90M
↑ +2.8% —
Net Income Profit after all expenses
$-91.80M
↓ -622.8% —
Operating Margin Operating profit as % of sales
-3.5%
↑ +32.7% 7th
FCF / Share Free cash flow per share
$-1.99
↓ -102.8% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
14
Financial Health ↑
27
Cash Quality ↓
25

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 24 quarters